Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Clinical impact of endoscopic ultrasound-guided through-the-needle microbiopsy in patients with pancreatic cysts

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{fd5cebf245f04e17a676c11588cc4bbc,
title = "Clinical impact of endoscopic ultrasound-guided through-the-needle microbiopsy in patients with pancreatic cysts",
abstract = "Background: The limited data on the utility of endoscopic ultrasound (EUS)-guided through-the-needle biopsies (TTNBs) in patients with pancreatic cystic lesions (PCLs) originate mainly from retrospective studies. Our aim was to determine the clinical impact of TTNBs, their added diagnostic value, and the adverse event rate in a prospective setting. Methods: This was a prospective, single-center, open-label controlled study. Between February 2018 and August 2019, consecutive patients presenting with a PCL of 15mm or more and referred for EUS were included. Primary outcome was a change in clinical management of PCLs following TTNB compared with cross-sectional imaging and cytology. Adverse events were defined according to the ASGE lexicon. Results: 101 patients were included. TTNBs led to a change in clinical management in 11.9% of cases (n=12). Of these, 10 had serous cysts and surveillance was discontinued, while one of the remaining two cases underwent surgery following diagnosis of a mucinous cystic neoplasm. The diagnostic yield of TTNBs for a specific cyst diagnosis was higher compared with FNA cytology (69.3% vs. 20.8%, respectively; P <0.001). The adverse event rate was 9.9% (n=10; 95% confidence interval 5.4%-17.3%), with the most common event being acute pancreatitis (n=9). Four of the observed adverse events were severe, including one fatal outcome. Conclusions: TTNBs resulted in a change of clinical management in about one in every 10 patients; however, the associated adverse event risk was substantial. Further studies are warranted to elucidate in which subgroups of patients the clinical benefit outweighs the risks.",
author = "Bojan Kovacevic and Pia Klausen and Rift, {Charlotte Vestrup} and Anders Toxv{\ae}rd and Hanne Grossjohann and Karstensen, {John G{\'a}sdal} and Lene Brink and Hazem Hassan and Evangelos Kalaitzakis and Jan Storkholm and Hansen, {Carsten Paln{\ae}s} and Hasselby, {Jane Preuss} and Peter Vilmann",
note = "Thieme. All rights reserved.",
year = "2021",
month = jan,
doi = "10.1055/a-1214-6043",
language = "English",
volume = "53",
pages = "44--52",
journal = "Endoscopy",
issn = "0013-726X",
publisher = "Georg/Thieme Verlag",
number = "1",

}

RIS

TY - JOUR

T1 - Clinical impact of endoscopic ultrasound-guided through-the-needle microbiopsy in patients with pancreatic cysts

AU - Kovacevic, Bojan

AU - Klausen, Pia

AU - Rift, Charlotte Vestrup

AU - Toxværd, Anders

AU - Grossjohann, Hanne

AU - Karstensen, John Gásdal

AU - Brink, Lene

AU - Hassan, Hazem

AU - Kalaitzakis, Evangelos

AU - Storkholm, Jan

AU - Hansen, Carsten Palnæs

AU - Hasselby, Jane Preuss

AU - Vilmann, Peter

N1 - Thieme. All rights reserved.

PY - 2021/1

Y1 - 2021/1

N2 - Background: The limited data on the utility of endoscopic ultrasound (EUS)-guided through-the-needle biopsies (TTNBs) in patients with pancreatic cystic lesions (PCLs) originate mainly from retrospective studies. Our aim was to determine the clinical impact of TTNBs, their added diagnostic value, and the adverse event rate in a prospective setting. Methods: This was a prospective, single-center, open-label controlled study. Between February 2018 and August 2019, consecutive patients presenting with a PCL of 15mm or more and referred for EUS were included. Primary outcome was a change in clinical management of PCLs following TTNB compared with cross-sectional imaging and cytology. Adverse events were defined according to the ASGE lexicon. Results: 101 patients were included. TTNBs led to a change in clinical management in 11.9% of cases (n=12). Of these, 10 had serous cysts and surveillance was discontinued, while one of the remaining two cases underwent surgery following diagnosis of a mucinous cystic neoplasm. The diagnostic yield of TTNBs for a specific cyst diagnosis was higher compared with FNA cytology (69.3% vs. 20.8%, respectively; P <0.001). The adverse event rate was 9.9% (n=10; 95% confidence interval 5.4%-17.3%), with the most common event being acute pancreatitis (n=9). Four of the observed adverse events were severe, including one fatal outcome. Conclusions: TTNBs resulted in a change of clinical management in about one in every 10 patients; however, the associated adverse event risk was substantial. Further studies are warranted to elucidate in which subgroups of patients the clinical benefit outweighs the risks.

AB - Background: The limited data on the utility of endoscopic ultrasound (EUS)-guided through-the-needle biopsies (TTNBs) in patients with pancreatic cystic lesions (PCLs) originate mainly from retrospective studies. Our aim was to determine the clinical impact of TTNBs, their added diagnostic value, and the adverse event rate in a prospective setting. Methods: This was a prospective, single-center, open-label controlled study. Between February 2018 and August 2019, consecutive patients presenting with a PCL of 15mm or more and referred for EUS were included. Primary outcome was a change in clinical management of PCLs following TTNB compared with cross-sectional imaging and cytology. Adverse events were defined according to the ASGE lexicon. Results: 101 patients were included. TTNBs led to a change in clinical management in 11.9% of cases (n=12). Of these, 10 had serous cysts and surveillance was discontinued, while one of the remaining two cases underwent surgery following diagnosis of a mucinous cystic neoplasm. The diagnostic yield of TTNBs for a specific cyst diagnosis was higher compared with FNA cytology (69.3% vs. 20.8%, respectively; P <0.001). The adverse event rate was 9.9% (n=10; 95% confidence interval 5.4%-17.3%), with the most common event being acute pancreatitis (n=9). Four of the observed adverse events were severe, including one fatal outcome. Conclusions: TTNBs resulted in a change of clinical management in about one in every 10 patients; however, the associated adverse event risk was substantial. Further studies are warranted to elucidate in which subgroups of patients the clinical benefit outweighs the risks.

UR - http://www.scopus.com/inward/record.url?scp=85089085851&partnerID=8YFLogxK

U2 - 10.1055/a-1214-6043

DO - 10.1055/a-1214-6043

M3 - Journal article

C2 - 32693411

VL - 53

SP - 44

EP - 52

JO - Endoscopy

JF - Endoscopy

SN - 0013-726X

IS - 1

ER -

ID: 60555799